EICHORCondition: Head and Neck Squamous Cell Carcinoma · Sponsor: Lyvgen Biopharma Holdings Limited
The purpose of this study is to assess the safety and efficacy of LVGN6051 (4-1BB agonistic antibody) combined with toripalimab (anti-PD-1 antibody) and paclitaxel (anti-tubulin chemotherapy) in patients with recurrent/metastatic head and neck squamous cell carcinoma who rapidly progress from previous neoadjuvant, curative, or adjuvant platinum-containing therapy, or who are currently contraindicated for platinum-containing treatment.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Anhui Cancer Hospital | Hefei, Anhui, China | — |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | — |
| Beijing Tongren Hospital Affiliated to Capital Medical University | Beijing, Beijing Municipality, China | — |
| Fujian cancer hospital | Fuzhou, Fujian, China | — |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | — |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | — |
| Henan cancer hospital | Zhengzhou, Henan, China | — |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | — |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | — |
| Xiangya Hospital Central South University | Changsha, Hunan, China | — |
| The Second Xiangya Hospital, Central South University | Changsha, Hunan, China | — |
| Hunan Cancer Hospital | Changsha, Hunan, China | — |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06378177